The TLR4 ligands MRP8 and MRP14 in the diagnosis and pathogenesis of systemic onset juvenile idiopathic arthritis by Frosch M, Viemann D, Wittkowski H, Foell D, Vogl T, Barczyk K, Wulffraat N, Roth J

Connect to this object online.

Autologous stem cell transplantation in autoimmune arthritis restores immune homeostasis by renewal of the natural Treg compartment by Prakken B, Boes M, Wulffraat N, Broere F, Wehrens E, Meerding J, Delemarre E, van den Broek T, van Wijk F

Connect to this object online.

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic J... by Ruperto N, Quartier P, Wulffraat N, Woo P, Loy A, Mouy R, Bader-Meunier B, Prakken B, Noseda E, Rordorf C

Connect to this object online.

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis by Prince FHM, Twilt M, Simon SCM, van Rossum MAJ, Armbrust W, Hoppenreijs EPAH, Kamphuis SSM, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat N, ten Cate R, van Suijlekom-Smit LWA

Connect to this object online.

The PRINTO provisional definition of remission in juvenile dermatomyositis by Kasapcopur O, Ganser G, Ferriani V, Penades I, Dolezalova P, Quartier P, Hofer M, Garay S, Wulffraat N, Pilkington C, Malattia C, Ravelli A, Miettunen P, Pistorio A, Lazarevic D, Melo-Gomes JA, Wierzbowska M, Martini A, Ruperto N

Connect to this object online.

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data by Espada G, Pardeo M, Chaitow J, Brown D, Allen R, Zulian F, Zuber Z, Wulffraat N, Joos R, Dolezalova P, Burgos-Vargas R, Woo P, Schneider R, Ruperto N, Brunner H, De Benedetti F, Flato B, Gerloni V, Horneff G, Wright S, Kenwright A, Lovell D, Martini A

Connect to this object online.